Literature DB >> 1888257

Gemfibrozil-induced myopathy.

G J Magarian1, L M Lucas, C Colley.   

Abstract

Drug-induced myopathy has been reported with use of lovastatin, nicotinic acid, and clofibrate. A particularly severe form, often accompanied by rhabdomyolysis, has been reported with the use of lovastatin and gemfibrozil; however, as far as we know, no case has been documented with use of gemfibrozil alone. Herein, we report the first case (to our knowledge of gemfibrozil-induced myopathy, confirmed by drug rechallenge.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1888257

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  12 in total

Review 1.  How well tolerated are lipid-lowering drugs?

Authors:  B Tomlinson; P Chan; W Lan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Primary care of the renal transplant patient.

Authors:  J D Pirsch; R Friedman
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

3.  In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.

Authors:  Jelena Tojcic; Marie-Odile Benoit-Biancamano; Michael H Court; Robert J Straka; Patrick Caron; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2009-08-06       Impact factor: 3.922

Review 4.  Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case.

Authors:  T K Lau; D R Leachman; R Lufschanowski
Journal:  Tex Heart Inst J       Date:  2001

5.  Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids.

Authors:  Paul S Phillips; Theodore P Ciaraldi; Dong-Lim Kim; M Anthony Verity; Tanya Wolfson; Robert R Henry
Journal:  Endocrine       Date:  2008-12-03       Impact factor: 3.633

6.  The Role of PPARα Activation in Liver and Muscle.

Authors:  Lena Burri; G Hege Thoresen; Rolf K Berge
Journal:  PPAR Res       Date:  2010-08-18       Impact factor: 4.964

Review 7.  Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

Authors:  C M Spencer; L B Barradell
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

8.  Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial.

Authors:  Atefeh Zandifar; Rahim Badrfam; Ahmad Shamabadi; Shakiba Jalilevand; Shayan Pourmirbabaei; Farbod Torkamand; Erfan Sahebolzamani; Shahin Akhondzadeh
Journal:  Iran J Psychiatry       Date:  2021-01

Review 9.  Combination drug therapy for combined hyperlipidemia.

Authors:  J R Guyton
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 3.955

10.  Statins: past and present.

Authors:  Rachel Hajar
Journal:  Heart Views       Date:  2011-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.